The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ENX-104 in participants with major depressive disorder with anhedonia (aMDD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
48
MAC Clinical Research
Blackpool, Lancashire, United Kingdom
MAC Clinical Research
Prescot, Merseyside, United Kingdom
MAC Clinical Research
Cannock, South Staffordshire, United Kingdom
MAC Clinical Research
Manchester, United Kingdom
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Time frame: From Day 1 up to Day 21
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.